Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:52U vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (FRA:52U) has a Buyback Yield % of 0.00 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 740 companies in the Biotechnology industry.
Is Hyloris Pharmaceuticals' Buyback Yield % too high?
Hyloris Pharmaceuticals' current Buyback Yield % is 0.00. Based on the distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 740 companies for Buyback Yield %. This places Hyloris Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (FRA:52U) is currently considered Possible Value Trap. The stock's GF Value™ is €8.35, compared to a current price of €4.29 — trading 48.6% below its estimated fair value. The current Buyback Yield % is 0.00. Hyloris Pharmaceuticals' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Hyloris Pharmaceuticals (FRA:52U), the current Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (FRA:52U) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.29 is trading 48.6% below its estimated GF Value™ of €8.35.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:52U:
Buyback Yield %: 0.00
GF Value™: €8.35 vs. price of €4.29 (48.6% below fair value)
No single metric tells the full story. See the FRA:52U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
68GF Score
Get the complete analysis for FRA:52U
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:52U has been successfully added to your 
